The Neuroscience Consortium funds pre-clinical neuroscience research at Massachusetts academic and research institutions. Companies currently participating in the Consortium include AbbVie, Biogen, Celgene. General Electric, Lundbeck, Merck, Novartis, and Sunovion Pharmaceuticals (Consortium Members).
Eligibility & Evaluation
Consortium Members have pooled their resources to fund the identification and validation of novel targets for the symptomatic treatment and modification of these chronic and debilitating neurological diseases. It is required all proposals be anchored in recognized human disease genetics and pathophysiology, or within pathways of known relevance to human disease, and should be translational, rather than exploratory. Examples of such proposals might include research that:
- Confirms or refutes the involvement of a particular pathway or mechanism in human disease;
- Identifies new molecular targets, or strengthens the case for a potential target, or rules out a suspected target;
- Establishes new and improved animal models of human disease in the identified focus areas, with established face and/or construct validity;
- Develops a method for manipulating or measuring a pathway of known human pathological relevance; or
- Identifies or validates a biomarker than can be used for drug discovery and/or development.
Impact on the Ecosystem
In July of 2013, the MLSC announced the first round awardees including three grants focused on Alzheimer’s Disease, two grants focused on neuropathic pain, and one grant each focused on Multiple Sclerosis and Parkinson’s Disease. For this second round, the Consortium has expanded the diseases of interest and is seeking proposals focused on neurodegenerative and neuroinflammatory diseases (such as AD, PD, MS, Huntington’s, ALS), neuropathic pain and treatment-resistant depression.
Connect with us to Learn More
If you have any questions regarding the application process, e-mail: firstname.lastname@example.org.